Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Brehm, Jessica H ^a   Scott, Yanille ^a,b   Koontz, Dianna L ^a   Perry, Steven ^a   Hammer, Scott ^c   Katzenstein, David ^d   Mellors, John W ^a   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; THYMIDINE DERIVATIVE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE; ADENOSINE TRIPHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MUTANT PROTEIN; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; BIOCHEMISTRY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; RNA CLEAVAGE; RNA SEQUENCE; VIRUS MUTATION; VIRUS RECOMBINANT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; GENETIC RECOMBINATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MUTATION; PHENOTYPE; PROTEIN TERTIARY STRUCTURE; RANDOMIZED CONTROLLED TRIAL; SITE DIRECTED MUTAGENESIS; VIROLOGY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECOMBINATION, GENETIC; RIBONUCLEASE H; RNA, VIRAL; ZIDOVUDINE;

EID: 84857412285     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031558     Document Type: Article

References (28)

1. Larder BA, Kemp SD, (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
2. Kellam P, Boucher CA, Larder BA, (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A 89: 1934-1938.
3. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, et al. (1996) Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 70: 5930-5934.
4. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, et al. (1996) An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 70: 8010-8018.
5. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, et al. (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72: 162-165.
6. Meyer PR, Matsuura SE, So AG, Scott WA, (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 95: 13471-13476.
7. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA, (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4: 35-43.
8. Tu X, Das K, Han Q, Bauman JD, Clark AD Jr, et al. (2010) Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol 17: 1202-1209.
9. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, et al. (2007) Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A 104: 317-322.
10. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK, (2007) Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 81: 6837-6845.
11. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, et al. (2008) HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A 105: 10943-10948.
12. Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN, Baumann J, Santos AF, et al. (2011) Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J Antimicrob Chemother 66: 702-708.
13. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 4: e335.
14. Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N, (2010) N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 24: 659-667.
15. von Wyl V, Ehteshami M, Symons J, Burgisser P, Nijhuis M, et al. (2010) Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. J Infect Dis 201: 1054-1062.
16. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, et al. (2007) Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 81: 7852-7859.
17. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, et al. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335: 1081-1090.
18. MMWR Morb Mortal Wkly Rep (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases Aug 14;36 (Suppl 1): 1S-15S.
19. Abecasis AB, Wang Y, Libin P, Imbrechts S, de Oliveira T, et al. Comparative performance of the REGA subtyping tool version 2 versus version 1. Infect Genet Evol 10: 380-385.
20. Shi C, Mellors JW, (1997) A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother 41: 2781-2785.
21. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW, (2005) In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 49: 1139-1144.
22. Le Grice SF, Gruninger-Leitch F, (1990) Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 187: 307-314.
23. Radzio J, Sluis-Cremer N, (2008) Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 73: 601-606.
24. Brehm JH, Mellors JW, Sluis-Cremer N, (2008) Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 47: 14020-14027.
25. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
26. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, et al. (2008) Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and-independent Mechanisms. J Biol Chem 283: 22222-22232.
27. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, et al. (2008) Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 82: 3261-3270.
28. von Wyl V, Ehteshami M, Demeter LM, Burgisser P, Nijhuis M, et al. (2010) HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. Clin Infect Dis 51: 620-628.